February 08, 2016
The acquisition of pharmaceutical company Amdipharm Mercury (AMCo) by Concordia Healthcare in September 2015—ranked among Lexpert’s Top Ten Deals of 2015—is the focus of a Q&A piece for Lexpert’s February issue featuring Torys partner and co-head of our M&A Practice John Emanoilidis. John led the Torys team representing Cinven, AMCo’s parent company; in the article, he discusses the approach of the teams involved to bring this deal to fruition amid growing turbulence in the U.S. pharmaceutical industry. Below is an excerpt of the article where John describes the atmosphere at the deal table.
Emanoilidis: The parties all believed that there continued to be good value in the deal and that the acquisition could still be completed in its original terms. The parties and their advisors worked very hard to make sure that happened, even in the face of what was happening to share prices across the sector.
To read the full article, click here.
Read about Torys’ involvement in the Cinven-Concordia deal here.